Article

How much survival is enough?

Yesterday, the FDA approved a new breast cancer chemotherapy called Halaven (eribulin). It was tested in women with metastatic disease that had several courses of chemotherapy already. This is a pretty hard-to-treat patient population, and Halaven extended survival by a median of 2.5 months.When we published yesterday's blog on the drug approval (New drug approved for breast cancer) we got a few comments on our facebook page about it (www.facebook.com/curemagazine).Comment: Just two and a half months? I pray to God my BC does not come back if that's the best they can do. :-(It is a scary thought. All the excitement about a new drug that does extend life, and then we hear it's only about 3 months. Without the drug, the median survival was about 10.6 months, with it, 13.1 months. Not something you want to hear if you have metastatic breast cancer. You want a cure, and rightfully so.But ... it's only the median. There are women who lived longer than the 13 months, but then some women did not live as long. It's also a trade-off with the side effects.It's also extra time. I think it's ironic that we ran Suzanne Lindley's blog about living with metastatic colorectal cancer (Three months of life...is it worth it?) a couple of weeks before a drug was approved that extended life about three months. Suzanne talked about hearing an oncologist at a medical meeting say, "Three months - why bother?" She responded by explaining that in late 2004 she was planning her funeral, but then she discovered a new treatment option that has worked for her. She's "hitchhiked" on various treatments over the years that have given her a month here, a year there, and has streatched it out for more than a decade. Of course, Suzanne's story isn't typical, but it does give us hope. Hope that three months may mean another milestone or another memory. It could also mean that it buys a patient time until a new clinical trial comes along or another drug approval.

Related Videos
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Related Content